Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Initial Public Offering	Series A Convertible Preferred Stock	Series A-1 Convertible Preferred Stock	Series B Convertible Preferred Stock	Common Stock	Common Stock Initial Public Offering	Additional Paid-in Capital	Additional Paid-in Capital Initial Public Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2020	$ (30,654)							$ 1,847			$ (32,501)
Balance, shares at Dec. 31, 2020						2,059,157
Temporary equity, Issuance of preferrred stock upon modification and conversion of notes				$ 38,911
Temporary equity, Issuance of preferrred stock upon modification and conversion of notes, shares				12,713,585
Issuance of preferrred stock upon modification and conversion of notes	1,735							1,735
Temporary equity, Acquisitions of Oppilan and Zomagen				$ 18,526
Temporary equity, Acquisitions of Oppilan and Zomagen, shares				6,052,911
Acquisitions of Oppilan and Zomagen	2,733							2,733
Acquisitions of Oppilan and Zomagen, shares						818,798
Temporary equity, Issuance of preferred stock and common stock, net of legal fees			$ 112,297		$ 50,809
Temporary equity, Issuance of preferred stock and common stock, net of legal fees, shares			12,533,905		4,029,275
Issuance of preferred stock and common stock, net		$ 158,815					$ 1	1,552	$ 158,814		(1,552)
Issuance of preferred stock and common stock, net, shares						507,133	10,893,554
Temporary equity, Conversion of tranche liability to Series A preferred stock and common stock			$ 3,978
Conversion of tranche liability to Series A preferred stock and common stock	3,058							3,058
Conversion of tranche liability to Series A preferred stock and common stock, shares						507,133
Temporary equity, Conversion of preferred stock to common stock in connection with initial public offering			$ (116,275)	$ (57,437)	$ (50,809)
Temporary equity, Conversion of preferred stock to common stock in connection with initial public offering, shares			(12,533,905)	(18,766,496)	(4,029,275)
Conversion of preferred stock to common stock in connection with initial public offering	224,521					$ 4		224,517
Conversion of preferred stock to common stock in connection with initial public offering, shares						35,329,676
Issuance of common stock upon exercise of stock options	65							65
Issuance of common stock upon exercise of stock options, shares						197,004
Issuance of common stock upon vesting of restricted common stock, shares						96,375
Stock-based compensation expense	2,730							2,730
Unrealized loss on marketable securities	(69)									$ (69)
Foreign currency translation	11									11
Net loss	(83,746)										(83,746)
Balance at Dec. 31, 2021	279,199					$ 5		397,051		(58)	(117,799)
Balance, shares at Dec. 31, 2021						50,408,830
Issuance of common stock from private placement, net of issuance costs	165,214					$ 1		165,213
Issuance of common stock from private placement, net of issuance costs,shares						5,350,000
Issuance of common stock upon exercise of stock options	$ 2,110							2,110
Issuance of common stock upon exercise of stock options, shares	959,066					959,066
Issuance of common stock upon vesting of restricted common stock, shares						241,792
Shares issued under employee stock purchase plan	$ 267							267
Shares issued under employee stock purchase plan, shares						21,157
Adjustment to offering expenses in the initial public offering	26							26
Stock-based compensation expense	16,570							16,570
Unrealized loss on marketable securities	(1,023)									(1,023)
Foreign currency translation	(42)									(42)
Net loss	(108,426)										(108,426)
Balance at Dec. 31, 2022	$ 353,895					$ 6		$ 581,237		$ (1,123)	$ (226,225)
Balance, shares at Dec. 31, 2022						56,980,845